查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018748

乳癌診斷市場：依技術、產品、生物標記、檢體類型和最終用戶分類－2026-2032年全球市場預測

Breast Cancer Diagnostics Market by Technology, Product, Biomarker, Sample Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，乳癌診斷市場價值將達到 76 億美元，到 2026 年將成長到 82 億美元，到 2032 年將達到 130.6 億美元，複合年成長率為 8.04%。

主要市場統計數據
基準年 2025 76億美元
預計年份：2026年 82億美元
預測年份 2032 130.6億美元
複合年成長率 (%) 8.04%

概述不斷發展的乳癌診斷市場，重點關注臨床效用和營運轉型之間的交集。

乳癌診斷正經歷快速變革時期，主要得益於檢體採集技術、檢體分析、影像技術和分子譜分析技術的同步發展。新的工具正在重塑從初步篩檢到最終診斷和治療分層的臨床路徑，而放射科、病理科和分子檢查室之間的跨學科合作對於實現精準醫療也變得日益重要。更豐富的資料流，包括數位乳房斷層合成影像、用於演算法審查的數位化免疫組化切片以及基於次世代定序的基因組特徵，正在增強臨床決策能力，這既為醫療服務提供者和產業帶來了機遇，也帶來了挑戰。

影像、組織取樣、病理自動化和分子分析技術的進步正在系統地重新定義診斷過程和臨床工作流程。

多項變革正在改變乳癌的檢測、分類和後續觀察方式。首先，影像技術正從類比影像轉向以數位影像為主的模式，透過磁振造影（MRI）和超音波，以及數位乳房斷層合成和先進的乳房X光攝影，增強病灶的表徵和分診。這些影像技術擴大與電腦工具結合，輔助放射科醫生解讀影像並確定切片檢查的優先順序。其次，切片檢查方法也日趨多樣化。針刺活體組織切片和手術技術的改進，在最大限度保留組織的同時，實現了更全面的後續檢查，從而影響了檢查室的工作流程和耗材需求。

2025 年美國關稅環境對診斷供應鏈、籌資策略和臨床獲得先進檢測的實際影響。

美國2025年實施的關稅政策和貿易措施為診斷設備和試劑的供應鏈帶來了巨大摩擦。進口關稅及相關合規要求推高了部分設備和耗材的成本，影響了採購計劃，並促使一些檢查室和醫院重新評估其供應商多元化策略。為此，採購團隊日益重視確保本地庫存，並加強合約條款以降低關稅波動帶來的風險。同時，製造商也正在探索國內生產和近岸外包，以減少跨境關稅的影響。

從技術架構、產品系列、生物標記、檢體類型和最終用戶需求等方面獲取可操作的細分洞察，以指導優先排序。

了解市場區隔對於使產品開發和商業化與臨床需求和購買行為相符至關重要。技術細分揭示了切片檢查、組織病理學、影像學和分子診斷領域的清晰趨勢。針刺活體組織切片和手術切片檢查的需求各不相同，這兩種方法都會影響檢體的完整性以及與下游檢測的兼容性。組織病理學工作流程分為免疫組織化學和染色系統，每種系統都需要相應的試劑組合和自動化選項。數位乳房斷層合成、乳房X光攝影、磁振造影和超音波等影像學方法在篩檢和診斷流程中佔據不同的位置，從而影響相應的資本投入和培訓。分子診斷包括螢光原位雜合技術（FISH）、基於PCR的方法和次世代定序（NGS），但靶向NGS和全基因測序對數據分析和檢查室基礎設施的需求不同，而基於PCR的方法又根據靈敏度和處理能力分為數字PCR和即時PCR。

美洲、歐洲、中東和非洲以及亞太地區的區域需求和實施差異決定了臨床應用和商業策略。

區域趨勢正在影響全球的技術應用、監管流程和報銷機制。在美洲，健全的臨床研究網路和醫院系統為先進影像和分子診斷平台的快速普及提供了支持，而供應鏈挑戰和政策轉變則影響著採購行為。在歐洲和中東及非洲，情況更為複雜。在西歐市場，數位病理學和綜合生物標記檢測的整合領先，而在該地區的新興市場，基礎設施和准入限制使得成本效益高且可靠的診斷方法成為優先考慮因素。監管協調和跨境合作的努力正在逐步加快創新從研究到實用化的進程。

競爭定位、夥伴關係和臨床檢驗如何重新定義乳癌診斷技術和服務提供領域的領導地位。

乳癌診斷領域的競爭格局呈現出傳統儀器製造商、新興分子診斷專家以及來自數位醫療領域的新進參與企業的局面。老牌製造商持續投資於影像系統、切片檢查設備和組織病理學儀器的漸進式創新，而新晉參與企業則專注於小眾分子檢測、靶向測序平台和軟體主導的診斷工具。隨著各公司努力將硬體功能與分析軟體和資訊服務結合，以提供端到端的診斷解決方案，策略夥伴關係和共同開發契約也變得越來越普遍。

為製造商、臨床領導者和保險公司提供實際有效的建議，以加速臨床部署，同時確保營運彈性。

產業領導者應優先考慮兼顧臨床影響和營運擴充性的投資。首先，製造商需要加快影像平台、實驗室設備和分子分析的整合，建構一個可互通的生態系統，從而簡化臨床醫生的工作流程並減少交接環節。其次，透過預測性維護、培訓和數據驅動的諮詢來改善服務模式，可以提高客戶維繫並降低醫療保健採購方的整體擁有成本。第三，企業應建構模組化產品線，以便在不中斷醫院和檢查室核心臨床服務的情況下，分階段進行升級和添加新功能。

一個強大的混合方法研究框架，結合了初步臨床發現、監管分析和工作流程映射，以支援戰略診斷情報。

本研究整合了同行評審文獻、監管指導文件、臨床試驗註冊數據以及對臨床實驗室技術人員、病理學家、放射科醫生和採購經理的訪談，從而構建了一個全面的診斷環境分析框架。定量數據和定性見解的交叉檢驗確保了對技術成熟度、臨床效用和商業性可行性的平衡解釋。調查方法特別強調繪製切片檢查、組織病理學、影像學和分子診斷的工作流程圖，以識別瓶頸和整合機會，同時也檢驗了耗材、設備和軟體服務的產品生命週期，以了解售後市場趨勢。

融合診斷模式的策略概述及將創新轉化為臨床影響所需的營運前提

總之，乳癌診斷領域正朝著影像學、組織學分析和分子譜分析更緊密融合的方向發展，並輔以軟體和服務，實現數據驅動的臨床決策。這些融合模式為提高診斷準確性、實現個人化治療選擇和最佳化診療路徑創造了機遇，但也需要健全的營運規劃和超越臨床專科的協作模式。投資於互通性、臨床有效性檢驗和在地化商業性模式的相關人員，將更有能力將技術潛力轉化為可衡量的患者獲益。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章乳癌診斷市場：依技術分類

  • 切片檢查
    • 針刺切片
    • 手術切片檢查
  • 組織病理學
    • 免疫組織化學
    • 染色系統
  • 診斷影像
    • 數位乳房斷層合成
    • 乳房X光檢查
    • MRI
    • 超音波
  • 分子診斷
    • FISH
    • NGS
      • 標靶NGS
      • 全基因組定序
    • 基於PCR的
      • 數位PCR
      • 即時PCR

第9章乳癌診斷市場：依產品分類

  • 消耗品
    • 試劑和試劑盒
    • 玻片和染色試劑
  • 裝置
    • 切片檢查裝置
    • 組織病理學設備
    • 影像系統
    • 序列器
  • 軟體和服務
    • 諮詢和維護
    • 數據分析軟體

第10章：以生物標記分類的乳癌診斷市場

  • BRCA
  • ER/PR
  • HER2
  • Ki-67

第11章檢體類型分類的乳癌診斷市場

  • 血
  • 血清
  • 組織

第12章乳癌診斷市場：依最終用戶分類

  • 癌症研究中心
  • 診斷檢查室
  • 醫院
  • 專科診所

第13章乳癌診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章乳癌診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章乳癌診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國乳癌診斷市場

第17章：中國乳癌診斷市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 4D Path Inc.
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Biodesix
  • Cardinal Health
  • Danaher Corporation
  • Epigenomics AG
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fluxion Biosciences Inc. by Cell Microsystems
  • FUJIFILM Holdings Corporation
  • General Electric Company
  • Hologic, Inc.
  • Illumina, Inc.
  • Koninklijke Philips NV
  • NanoString Technologies, Inc.
  • NeoGenomics Laboratories
  • Olea Medical
  • OncoGenomX
  • Paragon Biosciences LLC by Catalent, Inc.
  • Provista Diagnostics, Inc. by Todos Medical
  • Quest Diagnostics Incorporated
  • Siemens Healthcare Private Limited
  • Thermo Fisher Scientific Inc.
Product Code: MRR-A26E0E57405A

The Breast Cancer Diagnostics Market was valued at USD 7.60 billion in 2025 and is projected to grow to USD 8.20 billion in 2026, with a CAGR of 8.04%, reaching USD 13.06 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.60 billion
Estimated Year [2026] USD 8.20 billion
Forecast Year [2032] USD 13.06 billion
CAGR (%) 8.04%

A concise orientation to the evolving breast cancer diagnostics landscape highlighting crossroads between clinical utility and operational transformation

Breast cancer diagnostics are undergoing a period of rapid transformation driven by parallel advances in sampling techniques, tissue analytics, imaging technologies, and molecular profiling. Emerging tools are reshaping clinical pathways from initial screening through definitive diagnosis and therapeutic stratification, while multidisciplinary collaboration between radiology, pathology, and molecular laboratories is increasingly essential to deliver precision care. Clinical decision-making is being augmented by richer data streams, including digital breast tomosynthesis images, immunohistochemistry slides digitized for algorithmic review, and genomic signatures from next-generation sequencing, all of which create both opportunity and complexity for providers and industry.

Against this backdrop, stakeholders must reconcile operational constraints with evolving standards of care. Adoption dynamics differ across end users such as cancer research centers, diagnostic laboratories, hospitals, and specialized clinics, and they are influenced by product segmentation spanning consumables, instruments, and software and services. Sample type considerations, whether blood, serum, or tissue, will continue to dictate workflow design and specimen logistics. In sum, the diagnostic landscape requires integrated strategic planning that balances clinical utility, workflow efficiency, and sustainable reimbursement pathways.

How advances in imaging, tissue sampling, histopathology automation, and molecular profiling are systematically redefining diagnostic pathways and clinical workflows

Several transformative shifts are changing how breast cancer is detected, classified, and monitored. First, imaging is moving from analogue to digital-first ecosystems, where digital breast tomosynthesis and advanced mammography are complemented by MRI and ultrasound to enhance lesion characterization and triage. These imaging modalities are increasingly integrated with computational tools that augment radiologist interpretation and prioritize cases for biopsy. Second, biopsy approaches are diversifying as needle and surgical techniques are refined to maximize tissue preservation while enabling comprehensive downstream testing, which in turn affects laboratory workflows and consumable demand.

Meanwhile, histopathology is evolving through greater adoption of immunohistochemistry and automated staining systems that increase throughput and reproducibility. Molecular diagnostics are also rising in clinical prominence; fluorescence in situ hybridization, PCR variants, and next-generation sequencing, including targeted panels and whole genome approaches, are delivering granular biomarker insights that drive therapeutic decisions. Complementing these technological shifts are new service models around data analysis software and consulting that support interpretation, quality control, and integration with electronic medical records. Collectively, these trends are reshaping procurement priorities, clinical pathways, and partnerships across the diagnostic ecosystem.

Practical implications of the United States tariff environment in 2025 on diagnostic supply chains, procurement strategies, and clinical access to advanced testing

Tariff policies and trade measures in the United States for 2025 have introduced practical friction into the supply chains that underpin diagnostic device and reagent availability. Import duties and related compliance requirements have elevated the cost of certain instruments and consumables, affecting procurement timelines and prompting some laboratories and hospitals to reassess supplier diversification strategies. In response, procurement teams are increasingly emphasizing localized inventory buffers and contractual clauses that mitigate tariff volatility, while manufacturers are evaluating onshore production and nearshoring to reduce exposure to cross-border tariff impacts.

As a result of these shifts, commercial strategies are adapting to preserve continuity of care and maintain access to critical testing modalities such as sequencers, imaging systems, and specialized staining reagents. Manufacturers and distributors are negotiating revised reseller agreements and exploring collaborative consignment models to stabilize supply. For clinical leaders, the tariff environment underscores the importance of supply chain resilience planning and scenario-based budgeting that account for regulatory and trade-driven costs, without compromising diagnostic quality or patient access to timely testing.

Actionable segmentation insights across technology architectures, product portfolios, biomarkers, sample types, and end-user demands to guide prioritization

Understanding market segmentation is essential to align product development and commercialization with clinical needs and purchasing behavior. Technology segmentation reveals distinct dynamics across biopsy, histopathology, imaging, and molecular diagnostics. Biopsy demand is differentiated by needle and surgical approaches, each influencing sample integrity and downstream assay compatibility. Histopathology workflows are bifurcated by immunohistochemistry and staining systems that require tailored reagent portfolios and automation options. Imaging modalities including digital breast tomosynthesis, mammography, MRI, and ultrasound are being positioned differently across screening and diagnostic pathways, with implications for capital investment and training. Molecular diagnostics encompass FISH, PCR-based methods, and next-generation sequencing, where targeted NGS and whole genome sequencing create divergent demands for data analysis and laboratory infrastructure, and PCR-based approaches split between digital PCR and real-time PCR in terms of sensitivity and throughput.

Product segmentation further delineates responsibilities across consumables, instruments, and software and services. Consumables such as reagents and slides have recurring revenue profiles and logistics sensitivities, whereas instruments-ranging from biopsy devices and histopathology instruments to imaging systems and sequencers-require long-term service and upgrade strategies. Software and services, including consulting, maintenance, and data analysis platforms, are increasingly important to extract clinical value from complex datasets. Biomarker segmentation, spanning BRCA, ER/PR, HER2, and Ki-67, dictates assay development priorities and informs clinical utility claims for companion diagnostics. Sample type considerations-blood, serum, and tissue-impact pre-analytical workflows, stability protocols, and the selection of appropriate molecular or imaging approaches. Finally, end user segmentation, covering cancer research centers, diagnostic laboratories, hospitals, and specialized clinics, highlights the need for adaptable solutions that can scale from research-grade assays to high-throughput clinical diagnostics.

Regional imperatives and adoption differentials across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine clinical adoption and commercial strategy

Regional dynamics shape technology adoption, regulatory pathways, and reimbursement practices across the globe. In the Americas, strong clinical research networks and hospital systems are supporting rapid uptake of advanced imaging and molecular diagnostic platforms, while supply chain considerations and policy shifts are influencing procurement behavior. Europe, the Middle East & Africa present a heterogeneous picture: Western European markets often lead in integrating digital pathology and comprehensive biomarker testing, while emerging markets in the region face infrastructure and access constraints that prioritize cost-effective and robust diagnostic modalities. Regulatory harmonization efforts and cross-border collaborations are gradually altering the pace at which innovations move from research to practice.

In the Asia-Pacific region, rapid infrastructure development and significant investments in healthcare technology are accelerating adoption of high-throughput molecular tools and imaging solutions, with an emphasis on scalability and localized manufacturing. Across all regions, differences in reimbursement frameworks, workforce capacity, and centralized versus decentralized laboratory models are the primary determinants of technology diffusion. Consequently, commercial strategies must be regionally nuanced, balancing standardized global value propositions with tailored implementations that reflect local clinical workflows and regulatory expectations.

How competitive positioning, partnerships, and clinical validation are redefining leadership in breast cancer diagnostic technologies and service delivery

Competitive dynamics in breast cancer diagnostics are defined by a mix of legacy instrument providers, emerging molecular specialists, and digital health entrants. Incumbent manufacturers continue to invest in incremental innovation for imaging systems, biopsy devices, and histopathology instrumentation, while newer entrants focus on niche molecular assays, targeted sequencing panels, and software-driven interpretation tools. Strategic partnerships and co-development agreements are increasingly common as companies seek to pair hardware capabilities with analytic software and data services to deliver end-to-end diagnostic solutions.

Moreover, consolidation through targeted acquisition of niche technology providers and alliances with clinical networks is reshaping go-to-market strategies. Strong aftermarket services and training programs are differentiating suppliers, especially for complex instruments that require ongoing maintenance and validation. Access to high-quality, curated clinical datasets and the ability to demonstrate clinical utility through peer-reviewed studies and real-world evidence are essential competitive advantages. Ultimately, companies that can integrate robust clinical validation, scalable manufacturing, and responsive commercial support will be best positioned to capture long-term engagement with hospitals, laboratories, and specialized clinics.

Practical, high-impact recommendations for manufacturers, clinical leaders, and payers to accelerate clinical adoption while safeguarding operational resilience

Industry leaders should prioritize investments that align clinical impact with operational scalability. First, manufacturers should accelerate integration between imaging platforms, laboratory instrumentation, and molecular analytics to create interoperable ecosystems that simplify clinician workflows and reduce handoffs. Second, enhancing service models-through predictive maintenance, training, and data-driven consulting-will increase customer retention and lower the total cost of ownership for institutional buyers. Third, companies should build modular product offerings that allow hospitals and laboratories to phase upgrades and add capabilities without disrupting core clinical services.

From a clinical perspective, stakeholders must emphasize assay standardization and cross-disciplinary training to ensure consistent interpretation of imaging and molecular results. Supply chain diversification and localized inventory strategies can mitigate tariff and trade risk while preserving access to critical consumables and instruments. Finally, payers and health systems should be engaged early to define value-based reimbursement pathways that recognize the downstream benefits of precise diagnostics, including reduced overtreatment and improved therapy matching. Taken together, these measures will enable sustainable adoption and maximize the clinical utility of emerging diagnostic innovations.

A robust mixed-methods research framework combining primary clinical insights, regulatory analysis, and workflow mapping to underpin strategic diagnostics intelligence

This research synthesized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and primary interviews with clinical laboratorians, pathologists, radiologists, and procurement leaders to create a holistic diagnostic landscape analysis. Quantitative inputs were triangulated with qualitative insights to ensure balanced interpretation of technology readiness, clinical utility, and commercial feasibility. The methodology placed particular emphasis on workflow mapping across biopsy, histopathology, imaging, and molecular diagnostics to identify bottlenecks and integration opportunities, and it examined product life cycles for consumables, instruments, and software-enabled services to understand aftermarket dynamics.

Data quality was assured through cross-validation of technical specifications, regulatory clearances, and device labeling, coupled with expert validation sessions to confirm clinical relevance. Regional analyses incorporated regulatory frameworks and reimbursement paradigms across the Americas, Europe, Middle East & Africa, and Asia-Pacific to reflect diverse adoption scenarios. Where possible, findings were corroborated with case studies and implementation examples to ground strategic recommendations in operational reality.

A strategic summation of converging diagnostic modalities and the operational prerequisites needed to translate innovation into clinical impact

In conclusion, the breast cancer diagnostics field is moving toward tighter integration of imaging, tissue-based analyses, and molecular profiling, supported by software and services that enable data-driven clinical decisions. These converging modalities are creating opportunities to refine diagnostic accuracy, personalize treatment selection, and streamline care pathways, but they also necessitate robust operational planning and collaborative models across clinical specialties. Stakeholders that invest in interoperability, clinical validation, and regionally adapted commercial approaches will be best positioned to translate technological promise into measurable patient benefit.

Looking forward, resilience in supply chains, agility in regulatory strategy, and demonstrable value to payers will be critical enablers of sustainable adoption. By aligning product roadmaps with real-world clinical workflows and by engaging early with end users and payers, diagnostic innovators and health systems can accelerate the adoption of high-value technologies while maintaining equitable access to timely and accurate breast cancer diagnosis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Cancer Diagnostics Market, by Technology

  • 8.1. Biopsy
    • 8.1.1. Needle Biopsy
    • 8.1.2. Surgical Biopsy
  • 8.2. Histopathology
    • 8.2.1. Immunohistochemistry
    • 8.2.2. Staining Systems
  • 8.3. Imaging
    • 8.3.1. Digital Breast Tomosynthesis
    • 8.3.2. Mammography
    • 8.3.3. MRI
    • 8.3.4. Ultrasound
  • 8.4. Molecular Diagnostics
    • 8.4.1. FISH
    • 8.4.2. NGS
      • 8.4.2.1. Targeted NGS
      • 8.4.2.2. Whole Genome Sequencing
    • 8.4.3. PCR-Based
      • 8.4.3.1. Digital PCR
      • 8.4.3.2. Real-Time PCR

9. Breast Cancer Diagnostics Market, by Product

  • 9.1. Consumables
    • 9.1.1. Reagents And Kits
    • 9.1.2. Slides And Staining Reagents
  • 9.2. Instruments
    • 9.2.1. Biopsy Devices
    • 9.2.2. Histopathology Instruments
    • 9.2.3. Imaging Systems
    • 9.2.4. Sequencers
  • 9.3. Software And Services
    • 9.3.1. Consulting And Maintenance
    • 9.3.2. Data Analysis Software

10. Breast Cancer Diagnostics Market, by Biomarker

  • 10.1. BRCA
  • 10.2. ER/PR
  • 10.3. HER2
  • 10.4. Ki-67

11. Breast Cancer Diagnostics Market, by Sample Type

  • 11.1. Blood
  • 11.2. Serum
  • 11.3. Tissue

12. Breast Cancer Diagnostics Market, by End User

  • 12.1. Cancer Research Centers
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Specialized Clinics

13. Breast Cancer Diagnostics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Breast Cancer Diagnostics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Breast Cancer Diagnostics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Breast Cancer Diagnostics Market

17. China Breast Cancer Diagnostics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 4D Path Inc.
  • 18.6. Abbott Laboratories
  • 18.7. Agilent Technologies, Inc.
  • 18.8. AstraZeneca PLC
  • 18.9. Becton, Dickinson and Company
  • 18.10. Bio-Rad Laboratories, Inc.
  • 18.11. Biocept, Inc.
  • 18.12. Biodesix
  • 18.13. Cardinal Health
  • 18.14. Danaher Corporation
  • 18.15. Epigenomics AG
  • 18.16. Exact Sciences Corporation
  • 18.17. F. Hoffmann-La Roche Ltd.
  • 18.18. Fluxion Biosciences Inc. by Cell Microsystems
  • 18.19. FUJIFILM Holdings Corporation
  • 18.20. General Electric Company
  • 18.21. Hologic, Inc.
  • 18.22. Illumina, Inc.
  • 18.23. Koninklijke Philips N.V.
  • 18.24. NanoString Technologies, Inc.
  • 18.25. NeoGenomics Laboratories
  • 18.26. Olea Medical
  • 18.27. OncoGenomX
  • 18.28. Paragon Biosciences LLC by Catalent, Inc.
  • 18.29. Provista Diagnostics, Inc. by Todos Medical
  • 18.30. Quest Diagnostics Incorporated
  • 18.31. Siemens Healthcare Private Limited
  • 18.32. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NEEDLE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SURGICAL BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY STAINING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL BREAST TOMOSYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MAMMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY FISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TARGETED NGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAL-TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SLIDES AND STAINING REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSULTING AND MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BRCA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY ER/PR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HER2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY KI-67, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL BREAST CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 279. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 281. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 282. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 283. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 284. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 285. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 286. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 287. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 288. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 289. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. GCC BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE AND SERVICES, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION BREAST CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGY, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY NGS, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PCR-BASED, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS BREAST CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS BREAST CANCER DIAGNOSTICS